Cambridge Investment Research Advisors Inc. bought a new position in Adamis Pharmaceuticals Corp (NASDAQ:ADMP) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,001 shares of the specialty pharmaceutical company’s stock, valued at approximately $36,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its holdings in shares of Adamis Pharmaceuticals by 27.1% in the third quarter. Vanguard Group Inc now owns 1,637,513 shares of the specialty pharmaceutical company’s stock worth $5,731,000 after buying an additional 348,645 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Adamis Pharmaceuticals by 27.1% in the third quarter. Vanguard Group Inc. now owns 1,637,513 shares of the specialty pharmaceutical company’s stock worth $5,731,000 after buying an additional 348,645 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Adamis Pharmaceuticals by 71.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,200,000 shares of the specialty pharmaceutical company’s stock worth $3,360,000 after buying an additional 500,000 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Adamis Pharmaceuticals by 203.2% in the third quarter. BlackRock Inc. now owns 889,440 shares of the specialty pharmaceutical company’s stock worth $3,113,000 after buying an additional 596,112 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Adamis Pharmaceuticals in the third quarter worth $481,000. 17.60% of the stock is currently owned by hedge funds and other institutional investors.

ADMP has been the topic of several research reports. Maxim Group set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 7th. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.56.

Shares of ADMP opened at $2.82 on Friday. Adamis Pharmaceuticals Corp has a fifty-two week low of $2.01 and a fifty-two week high of $5.10. The firm has a market capitalization of $133.66 million, a P/E ratio of -3.13 and a beta of 1.45.

WARNING: This story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2019/03/15/cambridge-investment-research-advisors-inc-buys-new-holdings-in-adamis-pharmaceuticals-corp-admp.html.

Adamis Pharmaceuticals Profile

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Recommended Story: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding ADMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamis Pharmaceuticals Corp (NASDAQ:ADMP).

Institutional Ownership by Quarter for Adamis Pharmaceuticals (NASDAQ:ADMP)

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.